干细胞领域知识发现平台

提升科研信息化水平
支撑研究所科技创新

  融合多源信息    打通数据孤岛
  挖掘知识关联    放大数据价值
  集成知识计算    促进知识发现

免费注册账号
查看全文和研发动态、知识导航以及收藏您喜欢的数据等操作,您需要注册一个免费帐户并登录。

写笔记

您最近的笔记
Drug Name:ICT-121
Regulatory Designations:     
Originator Company: ImmunoCellular Therapeutics Ltd Active Companies: ImmunoCellular Therapeutics Ltd
Last Change Date: 2018-08-16

extract

ImmunoCellular Therapeutics is developing ICT-121, an autologous dendritic cell vaccine created using Cedars-Sinai Medical Center ' peptide technology, which elicits a T-cell response targeting CD133-positive cancer stem cells (CSCs), for the potential treatment of cancers, including a brain cancer, recurrent glioblastoma multiforme, ovarian, pancreatic, and breast cancers [ 923863 ], [ 1110306 ], [ 1388254 ], [ 1458405 ], [ 1529481 ]. In July 2013, a phase I trial was initiated in recurrent


Other Drug Names:

CD133 modulating peptide (recurrent glioblastoma multiforme), ImmunoCellular Therapeutics; CD133 modulating peptides, Cedars-Sinai Medical Center; CD133 modulating peptides, ImmunoCellular Therapeutics; ICT-121; cancer stem cell vaccines, ImmunoCellular Therapeutics

Technologies

Biological therapeutic; Cell therapy; Parenteral formulation unspecified; Peptide

Development Status (Current)

ImmunoCellular Therapeutics Ltd: US: Phase 1 Clinical: Glioblastoma: 30-Jul-2013

Development Status (History)

ImmunoCellular Therapeutics Ltd: US: Discovery: Cancer: 09-Jul-2008

Drug Development Phase

[Glioblastoma: Phase 1 Clinical: US]

Therapy Area:

Cancer


Highest Status

Phase 1 Clinical


Target-based Actions

Prominin 1 modulator


Other Actions

Anticancer; Dendritic cell vaccine; Therapeutic vaccine


Active Indications

Glioblastoma